Dr. Krespi is a board certified Otolaryngologist-Head and Neck Surgery at North Shore-LIJ and Professor of Clinical Otolaryngology at Columbia University College of Physicians and Surgeons. Dr. Krespi graduated from medical school at Technion in Israel and completed his residency training at Mount Sinai Medical Center in New York. After his fellowship at Mt. Sinai, he was Associate Professor at Northwestern University Medical School in Chicago. He was Professor and Chairman of Otolaryngology at SUNY-Health Science Center in Brooklyn and Chairman at St Lukes-Roosevelt Hospital. Dr. Krespi has published over 160 scientific medical articles, and has served as editor on four text books and written over 60 book chapters. He is one of the world’s leading experts in laser surgery, endoscopic sinus surgery, surgery to relieve snoring and sleep apnea and oral malodor. Dr. Krespi is nationally and internationally recognized and has received numerous awards and honors in his field.
David O. Volpi, MD, FACS
Dr. Volpi is a Fellow of the American Academy of Sleep Medicine (AASM), the American Medical Association (AMA), the American College of Surgeons, the Medical Society of the State of New York, the New York County Medical Society, the American Academy of Otolaryngology—Head and Neck Surgery, the American Academy of Facial Plastic and Reconstructive Surgeons and the American Rhinologic Society. Dr. Volpi is one of New York City’s foremost snoring specialists and head of eOs Sleep, formerly the Manhattan Snoring and Sleep Center. As an Ear, Nose and Throat surgeon in his private practice for more than twenty years, he has provided expert care for all ENT disorders and diseases, with a specialty in snoring and sleep apnea treatment.
Alexander K. Arrow, MD, CFA
Chief Executive Officer and Director
Dr. Arrow comes to lead Zelegent, Inc. from Biolase, Inc. (NASDAQ: BIOL), the world’s lead manufacturer of dental lasers, where he served as a President and Chief Operating Officer, a Director, and Chair of the Audit and Compensation committees of the Board of Directors. Prior to Biolase, Dr. Arrow was the Chief Medical Officer of Stanford-affiliated neuroscience company Circuit Therapeutics, Inc., and prior to that he spent five years as the Chief Financial Officer of cardiovascular device manufacturer Arstasis, Inc. As CFO of Arstasis, he worked with future Zelegent VP of Regulatory and Clinical Affairs David Humbert, and future Zelegent VP of Engineering Joe Paraschac.
Before entering medical device manufacturer operating roles, Dr. Arrow spent nine years running medical technology equity research at three Wall Street firms, the last five years at Lazard. He also served as the Chief Financial Officer of the Patent & License Exchange, Inc. He has an MD from Harvard Medical School and began his surgical residency at the UCLA Medical Center before leaving to go into business.
Dr. Rui Avelar is the Chief Medical Officer for ALPHAEON®. He brings extensive experience in both clinical and industry roles to the Zelegent Board, in devices, pharmaceuticals, drug-device combinations and biologics. After his medical education, Dr. Avelar spent 20 years in private practice in Sports Medicine in Vancouver, including consulting for a number of Canadian National Teams and serving as the team physician for the Vancouver Canucks (an NHL franchise) for over ten years.
After his clinical practice, Dr. Avelar began his business career as a Wall Street buyside and sellside medical technology equity analyst. When he switched to industry, he spent 10 years at Angiotech Pharmaceuticals Inc., initially as the VP of Investor Relations, then the Chief Medical Officer, in charge of Regulatory, Clinical Operations, Clinical Development, Medical Affairs, Medical Writing, Statistics, Safety and Quality. He then served as the Chief Medical Officer for Allergan Medical for three years, with Clinical Development, Clinical Operations, Safety, Medical Writing, Statistics and Regulatory all reporting in to him.
Dr. Avelar received his medical degree from the University of Toronto and subsequently completed training accreditation in Sports Medicine from the Canadian Academy of Sports Medicine.
Bob Rhatigan is the President and Chief Operating Officer of ALPHAEON®’s, and has been since 2014. His background is in developing leading brands in medical aesthetics. Before ALPHAEON, he spent 17 years at Allergan, Inc., most recently as Senior VP, General Manager and Chief Executive of SkinMedica®, Inc. during which he was responsible for the integration of SkinMedica into Allergan, Inc. He also led the global SkinMedica® business, including R&D, commercialization, manufacturing and operations.
Prior to this role, Bob served as Senior VP of Allergan’s Facial Aesthetic business, during which he led the launches of BOTOX® Cosmetic, JUVÉDERM® and LATISSE® in the US. Under his leadership, Allergan’s Facial Aesthetics business received the highest customer satisfaction rating in medical aesthetics for seven consecutive years, and became the enormous business it is today. Prior to Allergan, Bob spent nine years at Procter and Gamble in sales and marketing.
CAUTION — Investigational device. Limited by Federal (or United States) law to investigational use.